The offering provides significant cash runway for Erasca's pipeline development but dilutes existing holders by ~10%. Monitor for upcoming clinical data catalysts that could justify the dilution; the upsized offering suggests strong institutional demand, which may support the stock near the $17.50 offering price in the near term.
ERAS drugs
ERAS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 15 $21.26entry
- T+1 · 4mo ago −10.54%α −9.99% · $19.02
- T+5 · 4mo ago −8.23%α −7.25% · $19.51
- T+20 · 3mo ago −12.61%α −14.95% · $18.58
- T+60 · 6w ago −27.28%α −29.81% · $15.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca priced an upsized public offering of 31,428,572 shares at $17.50 per share, raising approximately $516 million in net proceeds ($593.5 million if the underwriters' option is exercised in full). The offering provides substantial cash to fund its RAS/MAPK pipeline and general corporate purposes, but dilutes existing shareholders by roughly 10%. The upsized size signals strong institutional demand, partially offsetting dilution concerns.
Key Facts
- Erasca priced an upsized public offering of 31,428,572 shares of common stock at $17.50 per share.
- Net proceeds expected to be approximately $516.0 million, or $593.5 million if the underwriters' 30-day option to purchase an additional 4,714,285 shares is exercised in full.
- Underwriters purchase price is $16.45 per share; offering expected to close July 15, 2026.
- Proceeds will be used to fund research and development of product candidates and other development programs, working capital, and general corporate purposes.
- The offering was upsized from the initially proposed $500 million to $550 million in gross proceeds.
Financial Impact
Dilution of approximately 9-11% based on current market cap of $5.6B; cash infusion of ~$516M net ($593.5M with option).
Risk Factors
- Dilution of approximately 9-11% from the new shares.
- Potential overhang from the underwriters' option to purchase additional shares.
- Clinical-stage biotech risk: no approved products; pipeline execution is key.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-303357 |
| Document: d371010d8k.htm | 0001193125-26-303357 |
| Document: d371010dex51.htm | 0001193125-26-303357 |
| Document: d371010dex992.htm | 0001193125-26-303357 |
| Document: d371010dex991.htm | 0001193125-26-303357 |
| Document: 0001193125-26-303357-index-headers.html | 0001193125-26-303357 |
| Document: 0001193125-26-303357-index.html | 0001193125-26-303357 |
| Document: 0001193125-26-303357.txt | 0001193125-26-303357 |
Track record
26 reports on ERAS
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers